Global Market Report

Neuroendocrine Carcinoma Market Report 2020-2030

Where is the Neuroendocrine Carcinoma market heading? If you are involved in this sector you must read this newly updated report.

SKU: PHA0608 Category: Tag: Code: PHA0608Pages: 171
Clear
โ† Back to category Therapeutic Drugs

Description

Neuroendocrine Carcinoma, our new study reveals trends, R&D progress, and predicted revenues
Where is the Neuroendocrine Carcinoma market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead
Our 150+ page report provides 87 tables, 47 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Neuroendocrine Carcinoma Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
– You find original analyses, with business outlooks and developments.
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are 3 segmentations of the Neuroendocrine Carcinoma market, with forecasts for 3 Therapies, 5 Sites, 4 Diagnostic Tools each forecasted at a global and regional level.

Global Neuroendocrine Carcinoma Market by Therapy
– Hemotherapy
– Radiation Therapy
– Radiofrequency Ablation (RFA)
– Local Excision
– Surgery

Global Neuroendocrine Carcinoma Market by Site
– Brain
– Gastrointestinal
– Lung
– Pancreas
– Others

Global Neuroendocrine Carcinoma Market by Diagnostic Tools
– Biopsy
– Imaging
– CT Scan
– X-Ray
– PET Scan
– Others
– Serology
– Urine Test
– Blood Test
– Molecular Test
– Others
– Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets:

– North America:
– U.S.
– Canada

– Latin America:
– Brazil
– Mexico
– Rest of Latin America

– Europe:
– Germany
– France
– UK
– Italy
– Spain
– Russia
– Rest of Europe

– Asia-Pacific:
– Japan
– China
– India
– Australia
– ASEAN
– Rest of Asia-Pacific

– MEA:
– GCC Countries
– South Africa
– Rest of MEA

The report also includes profiles and for some of the leading companies in the Neuroendocrine Carcinoma market, with a focus on this segment of these companies’ operations.

There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and India, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth
Overall world revenue for Neuroendocrine Carcinoma Market will surpass $1.7 billion in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Neuroendocrine Carcinoma Market report helps you
In summary, our 150+ page report provides you with the following knowledge:

– Revenue forecasts to 2030 for 3 segmentations of the Neuroendocrine Carcinoma market, with forecasts for 3 Therapies, 5 Sites, 4 Diagnostic Tools, each forecasted at a global and regional level, discover the industry’s prospects, finding the most lucrative places for investments and revenues

– Revenue forecasts to 2030 for 5 regional and 17 key national markets , See forecasts for the Neuroendocrine Carcinoma market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, ASEAN countries, GCC Countries and South Africa.

– Prospects for established firms and those seeking to enter the market, including company profiles for 16 major companies involved in the Neuroendocrine Carcinoma Market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.

Visiongain’s study is for everybody needing commercial analyses for the Neuroendocrine Carcinoma market and leading companies. You will find data, trends and predictions.

Get our report today The Neuroendocrine Carcinoma Market Forecast 2020-2030: Revenue Prospects by Therapy {Hemotherapy, Radiation Therapy (Radiofrequency Ablation (RFA) and Local Excision), Surgery}, Site (Brain, Gastrointestinal, Lung, Pancreas, Others), Diagnostic Tools {Biopsy, Imaging (CT scan, X-Ray, PET Scan and Others), Serology (Urine Test, Blood Test, Molecular Test, And Others), Others}, and Geography.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com

1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain

2. Neuroendocrine Carcinoma Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Global Neuroendocrine Carcinoma Market Size and Forecast
2.3. Market Dynamics
2.3.1. Market Drivers
2.3.1.1. Growing incidence of neuroendocrine tumors (NETs)
2.3.1.2. Growing research & development to treat cancer
2.3.1.3. Rising government investments
2.3.1.4. Product Approvals
2.3.1.5. Growing number of clinical trials
2.3.2. Market Restraints
2.3.2.1. Lack of adequate healthcare infrastructure
2.3.2.2. Shortage of trained personnel
2.3.3. Opportunities
2.3.3.1. Emerging Markets
2.3.3.2. Growing government and private investments to meet the increasing demand for cancer treatment
2.3.3.3. Improving reimbursement scenario
2.3.4. Global Neuroendocrine Carcinoma Market: Trends
2.3.5. Mergers and Acquisitions
2.3.6. Entry of New Market Players

3. Global Neuroendocrine Carcinoma Market Analysis and Forecast, By Therapy
3.1. Introduction
3.1.1. Global Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Therapy
3.2. Global Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
3.2.1. Hemotherapy
3.2.2. Radiation Therapy
3.2.3. Surgery
3.3. Global Neuroendocrine Carcinoma Attractiveness Index, By Therapy

4. Global Neuroendocrine Carcinoma Market Analysis and Forecast, By Site
4.1. Introduction
4.1.1. Global Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Site
4.1.2. Global Neuroendocrine Carcinoma Market Share Comparison, By Site (2018 & 2030)
4.2. Global Neuroendocrine Carcinoma Market Size and Forecast, By Site
4.2.1. Brain
4.2.2. Gastrointestinal
4.2.3. Lung
4.2.4. Pancreas
4.2.5. Others
4.3. Global Neuroendocrine Carcinoma Attractiveness Index, By Site

5. Global Neuroendocrine Carcinoma Market Analysis and Forecast, By Diagnostic Tools
5.1. Introduction
5.1.1. Global Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Diagnostic Tools
5.1.2. Global Neuroendocrine Carcinoma Market Share Comparison, By Diagnostic Tools (2018 & 2030)
5.2. Global Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
5.2.1. Biopsy
5.2.2. Imaging
5.2.3. Serology
5.2.4. Others
5.3. Global Neuroendocrine Carcinoma Attractiveness Index, By Diagnostic Tools

6. Global Neuroendocrine Carcinoma Market Analysis and Forecast, By Region
6.1. Introduction
6.1.1. Global Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Region
6.1.2. Global Neuroendocrine Carcinoma Market Share Comparison, By Region (2018 & 2030)
6.2. Global Neuroendocrine Carcinoma Market Size and Forecast, By Region
6.2.1. North America (U.S., Canada)
6.2.2. Latin America (Brazil, Mexico, Rest of Latin America)
6.2.3. Europe (UK, France, Germany, Italy, Spain, Russia, RoEU)
6.2.4. Asia Pacific (Japan, China, India, ASEAN, Australia, RoAPAC)
6.2.5. MEA (GCC, South Africa, RoMEA)
6.3. Global Neuroendocrine Carcinoma Market Attractiveness Index, By Region

7. North America Neuroendocrine Carcinoma Market Analysis and Forecast, 2020-2030
7.1. Introduction
7.1.1. North America Neuroendocrine Carcinoma Market
7.1.2. North America Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Country
7.2. North America Neuroendocrine Carcinoma Market Size and Forecast, By Country
7.2.1. The U.S. Neuroendocrine Carcinoma Market
7.2.2. Canada Neuroendocrine Carcinoma Market
7.3. North America Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
7.4. North America Neuroendocrine Carcinoma Market Size and Forecast, By Site
7.5. North America Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
7.6. North America Neuroendocrine Carcinoma Market Attractiveness Index, By Country

8. Latin America Neuroendocrine Carcinoma Market Analysis and Forecast, 2020-2030
8.1. Introduction
8.1.1. Latin America Neuroendocrine Carcinoma Market
8.1.2. Latin America Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Country
8.2. Latin America Neuroendocrine Carcinoma Market Size and Forecast, By Country
8.2.1. Brazil Neuroendocrine Carcinoma Market
8.2.2. Mexico Neuroendocrine Carcinoma Market
8.2.3. Rest of Latin America Neuroendocrine Carcinoma Market
8.3. Latin America Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
8.4. Latin America Neuroendocrine Carcinoma Market Size and Forecast, By Site
8.5. Latin America Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
8.6. Latin America Neuroendocrine Carcinoma Market Attractiveness Index, By Country

9. Europe Neuroendocrine Carcinoma Market Analysis and Forecast, 2020-2030
9.1. Introduction
9.1.1. Europe Neuroendocrine Carcinoma Market
9.1.2. Europe Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Country
9.2. Europe Neuroendocrine Carcinoma Market Size and Forecast, By Country
9.2.1. U.K. Neuroendocrine Carcinoma Market
9.2.2. France Neuroendocrine Carcinoma Market
9.2.3. Germany Neuroendocrine Carcinoma Market
9.2.4. Italy Neuroendocrine Carcinoma Market
9.2.5. Spain Neuroendocrine Carcinoma Market
9.2.6. Russia Neuroendocrine Carcinoma Market
9.2.7. Rest of Europe Neuroendocrine Carcinoma Market
9.3. Europe Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
9.4. Europe Neuroendocrine Carcinoma Market Size and Forecast, By Site
9.5. Europe Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
9.6. Europe Neuroendocrine Carcinoma Market Attractiveness Index, By Country

10. Asia Pacific Neuroendocrine Carcinoma Market Analysis and Forecast, 2020-2030
10.1. Introduction
10.1.1. Asia Pacific Neuroendocrine Carcinoma Market
10.1.2. Asia Pacific Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Country
10.2. Asia Pacific Neuroendocrine Carcinoma Market Size and Forecast, By Country
10.2.1. China Neuroendocrine Carcinoma Market
10.2.2. India Neuroendocrine Carcinoma Market
10.2.3. Australia Neuroendocrine Carcinoma Market
10.2.4. ASEAN Neuroendocrine Carcinoma Market
10.2.5. Japan Neuroendocrine Carcinoma Market
10.2.6. Rest of Asia Pacific Neuroendocrine Carcinoma Market
10.3. Asia Pacific Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
10.4. Asia Pacific Neuroendocrine Carcinoma Market Size and Forecast, By Site
10.5. Asia Pacific Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
10.6. Asia Pacific Neuroendocrine Carcinoma Market Attractiveness Index, By Country

11. MEA Neuroendocrine Carcinoma Market Analysis and Forecast, 2020-2030
11.1. Introduction
11.1.1. MEA Neuroendocrine Carcinoma Market
11.1.2. MEA Neuroendocrine Carcinoma Market, Annual Growth Rate Comparison, By Country
11.2. MEA Neuroendocrine Carcinoma Market Size and Forecast, By Country
11.2.1. GCC Neuroendocrine Carcinoma Market
11.2.2. South Africa Neuroendocrine Carcinoma Market
11.2.3. Rest of MEA Neuroendocrine Carcinoma Market
11.3. MEA Neuroendocrine Carcinoma Market Size and Forecast, By Therapy
11.4. MEA Neuroendocrine Carcinoma Market Size and Forecast, By Site
11.5. MEA Neuroendocrine Carcinoma Market Size and Forecast, By Diagnostic Tools
11.6. MEA Neuroendocrine Carcinoma Market Attractiveness Index, By Country

12. Leading Companies in the Neuroendocrine Carcinoma Market
12.1. Competition Dashboard
12.2. Company Share Analysis
12.3. Leading Players
12.4. AbbVie Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance (2016-2018)
12.4.4. Recent Initiatives
12.5. Aegis Therapeutics
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance (2016-2018)
12.5.4. Recent Initiatives
12.6. Amgen Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance (2016-2018)
12.6.4. Recent Initiatives
12.7. AVEO Pharmaceuticals, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance (2016-2018)
12.7.4. Recent Initiatives
12.8. Boehringer Ingelheim GmbH
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance (2016-2018)
12.8.4. Recent Initiatives
12.9. Chiasma Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance (2016-2018)
12.9.4. Recent Initiatives
12.10. Dauntless Pharmaceuticals
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance (2016-2018)
12.10.4. Recent Initiatives
12.11. Delcath Systems Inc.
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance (2016-2018)
12.11.4. Recent Initiatives
12.12. Exelixis, Inc.
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance (2016-2018)
12.12.4. Recent Initiatives
12.13. Hutchison MediPharma Limited
12.13.1. Company Overview
12.13.2. Product Offerings
12.13.3. Financial Performance (2016-2018)
12.13.4. Recent Initiatives
12.14. Ispen
12.14.1. Company Overview
12.14.2. Product Offerings
12.14.3. Financial Performance (2016-2018)
12.14.4. Recent Initiatives
12.15. Jubilant Life Sciences Ltd. (Jubilant DraxImage)
12.15.1. Company Overview
12.15.2. Product Offerings
12.15.3. Financial Performance (2016-2018)
12.15.4. Recent Initiatives
12.16. Novartis AG
12.16.1. Company Overview
12.16.2. Product Offerings
12.16.3. Financial Performance (2016-2018)
12.16.4. Recent Initiatives
12.17. Pfizer
12.17.1. Company Overview
12.17.2. Product Offerings
12.17.3. Financial Performance (2016-2018)
12.17.4. Recent Initiatives
12.18. Progenics Pharmaceuticals, Inc.
12.18.1. Company Overview
12.18.2. Product Offerings
12.18.3. Financial Performance (2016-2018)
12.18.4. Recent Initiatives
12.19. Tarveda Therapeutics
12.19.1. Company Overview
12.19.2. Product Offerings
12.19.3. Financial Performance (2016-2018)
12.19.4. Recent Initiatives

13. Conclusion

14. Glossary

LIST OF TABLES
Table 1 Global Neuroendocrine Carcinoma Market Size, By Region, 2020-2030 (USD Mn, CAGR%)
Table 2 Global Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 3 Global Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 4 Global Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 5 North America: Neuroendocrine Carcinoma Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 6 North America: Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 7 North America: Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 8 North America: Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 9 U.S. Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 10 U.S. Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 11 U.S. Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 12 Canada Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 13 Canada Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 14 Canada Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 15 Latin America: Neuroendocrine Carcinoma Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 16 Latin America: Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 17 Latin America: Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 18 Latin America: Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 19 Brazil Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 20 Brazil Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 21 Brazil Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 22 Mexico Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 23 Mexico Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 24 Mexico Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 25 Rest of Latin America Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 26 Rest of Latin America Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 27 Rest of Latin America Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 28 Europe: Neuroendocrine Carcinoma Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 29 Europe: Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 30 Europe: Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 31 Europe: Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 32 Germany Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 33 Germany Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 34 Germany Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 35 UK Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 36 UK Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 37 UK Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 38 France Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 39 France Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 40 France Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 41 Italy Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 42 Italy Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 43 Italy Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 44 Spain Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 45 Spain Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 46 Spain Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 47 Russia Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 48 Russia Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 49 Russia Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 50 Rest of Europe Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 51 Rest of Europe Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 52 Rest of Europe Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 53 APAC: Neuroendocrine Carcinoma Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 54 APAC: Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 55 APAC: Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 56 APAC: Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 57 Japan Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 58 Japan Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 59 Japan Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 60 China Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 61 China Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 62 China Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 63 India Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 64 India Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 65 India Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 66 Australia Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 67 Australia Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 68 Australia Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 69 ASEAN Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 70 ASEAN Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 71 ASEAN Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 72 Rest of APAC Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 73 Rest of APAC Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 74 Rest of APAC Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 75 MEA: Neuroendocrine Carcinoma Market Size, By Country, 2020-2030 (USD Mn, CAGR%)
Table 76 MEA: Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 77 MEA: Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 78 MEA: Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 79 GCC Countries Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 80 GCC Countries Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 81 GCC Countries Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 82 South Africa Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 83 South Africa Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 84 South Africa Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)
Table 85 Rest of MEA Neuroendocrine Carcinoma Market Size, By Therapy, 2020-2030 (USD Mn, CAGR%)
Table 86 Rest of MEA Neuroendocrine Carcinoma Market Size, By Site, 2020-2030 (USD Mn, CAGR%)
Table 87 Rest of MEA Neuroendocrine Carcinoma Market Size, By Diagnostic Tools, 2020-2030 (USD Mn, CAGR%)

LIST OF FIGURES
Figure 1 Neuroendocrine Carcinoma Market Segmentation
Figure 2 Drivers, Restraints, Opportunities, and Challenges in the Neuroendocrine Carcinoma Market
Figure 3 Value Chain Analysis
Figure 4 Porter's Five Forces Analysis
Figure 5 Global Neuroendocrine Carcinoma Market, By Therapy (2020-2030)
Figure 6 Global Neuroendocrine Carcinoma Market, By Site (2020-2030)
Figure 7 Global Neuroendocrine Carcinoma Market, By Diagnostic Tools (2020-2030)
Figure 8 Global Neuroendocrine Carcinoma Market, By Region
Figure 9 North America Neuroendocrine Carcinoma Market Snapshot
Figure 10 U.S. Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 11 Canada Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 12 Europe Neuroendocrine Carcinoma Market Snapshot
Figure 13 Germany Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 14 France Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 15 UK Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 16 Italy Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 17 Spain Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 18 Russia Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 19 APAC Neuroendocrine Carcinoma Market Snapshot
Figure 20 Japan Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 21 China Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 22 India Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 23 Australia Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 24 ASEAN Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 25 Latin America Neuroendocrine Carcinoma Market Snapshot
Figure 26 Brazil Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 27 Mexico Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 28 MEA Neuroendocrine Carcinoma Market Snapshot
Figure 29 GCC Countries Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 30 South Africa Neuroendocrine Carcinoma Market, 2020-2030 (USD Mn)
Figure 31 Company Market Share Analysis
Figure 32 AbbVie Inc. Financial Snapshot
Figure 33 Aegis Therapeutics Financial Snapshot
Figure 34 Amgen Inc. Financial Snapshot
Figure 35 AVEO Pharmaceuticals, Inc. Financial Snapshot
Figure 36 Boehringer Ingelheim GmbH Financial Snapshot
Figure 37 Chiasma Inc. Financial Snapshot
Figure 38 Dauntless Pharmaceuticals Financial Snapshot
Figure 39 Delcath Systems Inc. Financial Snapshot
Figure 40 Exelixis, Inc. Financial Snapshot
Figure 41 Hutchison MediPharma Limited Financial Snapshot
Figure 42 Ispen Financial Snapshot
Figure 43 Jubilant Life Sciences Ltd. (Jubilant DraxImage) Financial Snapshot
Figure 44 Novartis AG Financial Snapshot
Figure 45 Pfizer Financial Snapshot
Figure 46 Progenics Pharmaceuticals, Inc. Financial Snapshot
Figure 47 Tarveda Therapeutics Financial Snapshot

AbbVie Inc.
Aegis Therapeutics
Amgen Inc.
AVEO Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Chiasma Inc.
Dauntless Pharmaceuticals
Delcath Systems Inc.
Exelixis, Inc.
Hutchison MediPharma Limited
Ispen
Jubilant Life Sciences Ltd. (Jubilant DraxImage)
Novartis AG
Pfizer
Progenics Pharmaceuticals, Inc.
Tarveda Therapeutics